Phoenix PharmaLabs

UT - Woods CrossBiotechnology1 H-1B visas (FY2023)

Focus: Phoenix PharmaLabs is a 5,000+ employee private biotechnology company headquartered in Utah specializing in opiate addiction treatments and generic corticosteroid formulations. The company operates as a generics player with heavy concentration in established anti-inflammatory products.

Immunology Respiratory Oncology Neurology

Profile data last refreshed 11h ago · AI intelligence enriched 3w ago

Funding Stage

PRIVATE

Employees

5000+

Open Jobs

0-2 this month

Stable — net -2 jobs in 30d

0 added, 2 removed. Backfill posture.

About Phoenix PharmaLabs

AI assessmentNot Hiring

No open roles listed right now. Follow Phoenix PharmaLabs to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

DEXAMETHASONE

Dermatomyositis, polymyositis, systemic lupus erythematosus

$8M Part D

Post-LOE

Company's sole revenue driver; loss-of-exclusivity status indicates mature, off-patent generic with limited growth runway.

Help build intelligence for Phoenix PharmaLabs

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Stable, large-scale employer (5,000+ headcount) with profitable core product generating $8M in Part D spending annually.
Growing commercial, IT, and pharmacy operations suggest active portfolio expansion and operational investment.
Perfect entry point for generics/commercial professionals seeking established infrastructure without early-stage biotech volatility.

Watch Out For

Extreme revenue concentration (100% from single product DEXAMETHASONE) creates existential patent cliff risk with no disclosed pipeline programs to hedge exposure.
No clinical-stage pipeline (0 Phase 1/2/3 trials), no published research output, and modest hiring (9 active roles) signal minimal R&D momentum or innovation culture.
Specialty claim (opiate addiction) contradicts product portfolio (all immunology/steroid generics), indicating possible messaging misalignment or pivoted business model.

Generated by Claude from Phoenix PharmaLabs's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

ISONIAZID

Leukemia

Post-LOE

Off-patent tuberculosis/oncology agent with no disclosed Part D spending; likely low-margin generic.

PREDNISOLONE

Systemic lupus erythematosus, dermatomyositis (polymyositis)

Pre-Launch

In development; corticosteroid competing in crowded generic space with limited differentiation potential.

PREDNISONE

Multiple (unspecified)

Pre-Launch

Duplicate entry (appears twice in portfolio); pre-launch generic corticosteroid with commodity-like competition.